Seasoned global healthcare executive to lead next phase of growth for Resonant
Resonant Clinical Solutions, a global provider of outsourced clinical trial solutions announced the appointment of Dr. Christophe Berthoux as its Chief Executive Officer, effective immediately.
Berthoux brings more than three decades of leadership experience in the pharmaceutical services industry, including senior roles across clinical research organizations, preclinical services, and patient recruitment solutions.
Health Technology Insights: Point32Health Named Top Community-Minded Organization
Most recently, Berthoux served as CEO of private equity-backed NAMSA, where he meaningfully scaled the business through a combination of organic and M&A-driven growth. Prior to NAMSA, he held CEO roles at Synexus, a patient recruitment business acquired by PPD, and CitoxLab, which was acquired by Charles River Laboratories. Earlier in his career, Berthoux spent nearly two decades at Charles River Laboratories in senior leadership roles across Europe and North America, culminating as its Chief Commercial Officer.
“We are thrilled to welcome Christophe to Resonant,” said David Wong, Partner at Audax. “We believe his track record of building and scaling global pharmaceutical-services companies through both organic and inorganic growth makes him the ideal leader to drive the next phase of Resonant’s evolution as a stand-alone business. We look forward to partnering with him to expand Resonant’s capabilities, customer base, and geographic reach, while continuing to provide high quality service to our customer base.”
Health Technology Insights: Veeva and Sarah Cannon Collaborate to Advance Oncology Trials
“I am honored to join Resonant at such an exciting time,” said Berthoux. “The company, and its existing well-respected brands, together have a long track record of differentiated customer service and deep expertise in clinical trial kitting, equipment and ancillary services, and biorepository management. I look forward to working with the talented team at Resonant to build on this foundation and continue to enhance our value proposition across our domestic and global customer base.”
The appointment of Berthoux marks an important milestone in Resonant’s evolution following Audax’ acquisition of the business from Avantor in 2024. Since joining the Audax portfolio, Resonant has initiated meaningful investments in infrastructure, operational excellence, and customer service, seeking to accelerate growth and scale its offering across clinical-trial services markets globally.
Health Technology Insights: LivaNova VNS Therapy Proven Effective for Severe Seizures
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – businesswire
